Despite the vast number of potential pancreatic cancer biomarkers, very few have been thoroughly evaluated and none to the extent of
carbohydrate antigen 19-9 (CA 19-9). This review provides a comprehensive review on the utility of serum CA 19-9 as a pancreatic cancer biomarker and its value in screening, diagnosis, staging, determination of resectability, early identification of recurrence and predicting treatment response. Methods A comphrensive literature #http://www.selleckchem.com/products/Trichostatin-A.html keyword# search was performed using PubMed with keywords “pancreatic cancer” “tumor markers” “CA 19-9″ “diagnosis” “screening” “prognosis” “resectability” and “recurrence”. All English language articles pertaining to the role of CA Inhibitors,research,lifescience,medical 19-9 in pancreatic cancer for the years 1979-2010 were critically analyzed to determine its utility as
a biomarker for pancreatic cancer. Discussion Koprowoski et al. first described CA 19-9 in colorectal cancer cell line (SW1116) using a monoclonal antibody (1116-NS-19-9) i.e. hybridoma technology in 1979 (6). CA 19-9 is also identified in the tissue and sera of patients with other gastrointestinal tumors including esophageal, gastric, biliary and pancreatic cancer (7). CA 19-9 also termed as sialyl Lewis-a (sLea), is expressed on the surface of Inhibitors,research,lifescience,medical cancer cells as a glycolipid and as an O-linked glycoprotein. CA 19-9 is derived from an aberrant pathway during production of its normal counterpart disialyl Lewis-a that has one extra sialic acid residue attached through a 2→6 linkage. Normally, Disialyl Lewis-a is expressed on the epithelial surface of digestive organs, acts as a ligand for monocytes and macrophages and helps in immunosurveillance.
Inhibitors,research,lifescience,medical Epigenetic silencing of the gene for 2→6 sialyl transferase during early stages of carcinogenesis leads to abnormal synthesis and accumulation of sialyl Lewis-a (CA 19-9). sLea Inhibitors,research,lifescience,medical may also play a role in cancer invasion/metastasis as it is known to be a ligand for endothelial cell E-selectin responsible for cell adhesion (7-11). CA 19-9 is related to the Lewis blood group antigens and only patients belonging to the Dacomitinib Le (α-β+) or Le (α+β-) blood groups will express the CA 19-9 antigen (7). Le (α-β-) phenotypes occur in 5-10% of population which lack the enzyme 1,4-fucosyl transferase required for antigen Imatinib Mesylate manufacturer epitope production, and as such limits the use of CA 19-9 as a universally applicable biomarker (12-15). Utility of CA 19-9 serum levels as a diagnostic and screening marker for pancreatic cancer An “ideal” tumor marker possesses high sensitivity enabling it to identify the disease in a screening population without symptoms. Several studies have explored the utility of CA 19-9 serum levels as a screening tool for pancreatic cancer in asymptomatic individuals as well as in patients with symptoms suspicious for pancreatic cancer (Table 1) (16,18,19). Kim et al.